Advertisement

Current Diabetes Reports

, Volume 11, Issue 5, pp 426–433 | Cite as

Pathogenic and Regulatory T Cells in Type 1 Diabetes: Losing Self-Control, Restoring It, and How to Take the Temperature

  • Slobodan CulinaEmail author
  • Roberto MalloneEmail author
Article

Abstract

The central role of T cells in type 1 diabetes pathogenesis is well established, but these cells continue to pose numerous challenges in understanding their dynamics and in following their modifications. Important progress has been recently made in pinpointing some novel antigens targeted by pathogenic T cells and the epitope sequences recognized. Studies on the interplay between effector T cells, their regulatory counterparts, and cells of the innate immune system have unraveled novel pathways and may inspire new therapeutic approaches. At the same time, the appreciation of the plasticity of regulatory T cells has raised important caveats on their use for cell-based therapies. Continuous development of T-cell assays exploring both pathogenic and regulatory players will be critical to “take the temperature” of undergoing disease progression and reversal.

Keywords

Epitopes Innate immunity Peripheral tolerance T-cell assays Type 1 diabetes 

Notes

Acknowledgments

Work performed in the laboratory is supported by the Juvenile Diabetes Research Foundation (JDRF grant no. 1-2008-106), European Foundation for the Study of Diabetes (EFSD), and Lilly European Diabetes Research Program, Programme Blanc “Immunotolerins” of the Agence Nationale de la Recherche and by the INSERM Avenir program. We gratefully acknowledge Anna Falaschi-Jones for editorial assistance.

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Arai T, Moriyama H, Shimizu M, et al. Administration of a determinant of preproinsulin can induce regulatory T cells and suppress anti-islet autoimmunity in NOD mice. Clin Immunol. 2010;136:74–82.PubMedCrossRefGoogle Scholar
  2. 2.
    Mallone R, Martinuzzi E, Blancou P, et al. CD8+ T-cell responses identify beta-cell autoimmunity in human type 1 diabetes. Diabetes. 2007;56:613–21.PubMedCrossRefGoogle Scholar
  3. 3.
    •• Skowera A, Ellis RJ, Varela-Calvino R, et al. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J Clin Invest 2008;118:3390–2. This study shows that a PPI epitope derived from the signal peptide is targeted by diabetogenic T cells and that its processing and presentation by β cells is regulated by glucose concentrations.PubMedGoogle Scholar
  4. 4.
    Toma A, Laika T, Haddouk S, et al. Recognition of human proinsulin leader sequence by class I-restricted T-cells in HLA-A*0201 transgenic mice and in human type 1 diabetes. Diabetes. 2009;58:394–402.PubMedCrossRefGoogle Scholar
  5. 5.
    Panina-Bordignon P, Lang R, van Endert PM, et al. Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med. 1995;181:1923–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Blancou P, Mallone R, Martinuzzi E, et al. Immunization of HLA class I transgenic mice identifies autoantigenic epitopes eliciting dominant responses in type 1 diabetes patients. J Immunol. 2007;178:7458–66.PubMedGoogle Scholar
  7. 7.
    Winer S, Tsui H, Lau A, Song A, Li X, et al. Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. Nat Med. 2003;9:198–205.PubMedCrossRefGoogle Scholar
  8. 8.
    Standifer NE, Ouyang Q, Panagiotopoulos C, et al. Identification of Novel HLA-A*0201-restricted epitopes in recent-onset type 1 diabetic subjects and antibody-positive relatives. Diabetes. 2006;55:3061–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Lieberman SM, Evans AM, Han B, et al. Identification of the beta cell antigen targeted by a prevalent population of pathogenic CD8+ T cells in autoimmune diabetes. Proc Natl Acad Sci USA. 2003;100:8384–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Dang M, Rockell J, Wagner R, et al. Human Type 1 diabetes is associated with T cell autoimmunity to zinc transporter 8. J Immunol. 2011;186:6056–63Google Scholar
  11. 11.
    •• Stadinski BD, Delong T, Reisdorph N, et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 2010;11:225–31. This paper identifies the target epitope of the diabetogenic CD4+ T-cell clone BDC2.5 isolated from NOD mice. This epitope is complexed with I-Ag7 with an unusual binding registry.PubMedCrossRefGoogle Scholar
  12. 12.
    Mannering SI, Harrison LC, Williamson NA, et al. The insulin A-chain epitope recognized by human T cells is posttranslationally modified. J Exp Med. 2005;202:1191–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Kent SC, Chen Y, Bregoli L, et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature. 2005;435:224–8.PubMedCrossRefGoogle Scholar
  14. 14.
    McLachlan JB, Catron DM, Moon JJ, Jenkins MK. Dendritic cell antigen presentation drives simultaneous cytokine production by effector and regulatory T cells in inflamed skin. Immunity. 2009;30:277–88.PubMedCrossRefGoogle Scholar
  15. 15.
    • Grinberg-Bleyer Y, Saadoun D, Baeyens A, et al. Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs. J Clin Invest 2010;120:4558–68. Teffs can boost the expansion and suppressive activity of Tregs, revealing a novel crosstalk pathway in diabetes development and protection.PubMedCrossRefGoogle Scholar
  16. 16.
    Chen X, Baumel M, Mannel DN, et al. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol. 2007;179:154–61.PubMedGoogle Scholar
  17. 17.
    Kassiotis G, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med. 2001;193:427–34.PubMedCrossRefGoogle Scholar
  18. 18.
    Liu J, Marino MW, Wong G, et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med. 1998;4:78–83.PubMedCrossRefGoogle Scholar
  19. 19.
    Grinberg-Bleyer Y, Baeyens A, You S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010;207:1871–8.Google Scholar
  20. 20.
    Chen W, Zhang L, Liang B, et al. Perceiving the avidity of T cell activation can be translated into peripheral T cell regulation. Proc Natl Acad Sci USA. 2007;104:20472–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Jiang H, Chess L. How the immune system achieves self-nonself discrimination during adaptive immunity. Adv Immunol. 2009;102:95–133.PubMedCrossRefGoogle Scholar
  22. 22.
    Wu Y, Zheng Z, Jiang Y, et al. The specificity of T cell regulation that enables self-nonself discrimination in the periphery. Proc Natl Acad Sci USA. 2009;106:534–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Jiang H, Chess L. The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1. Annu Rev Immunol. 2000;18:185–216.PubMedCrossRefGoogle Scholar
  24. 24.
    • Jiang H, Canfield SM, Gallagher MP, et al. HLA-E-restricted regulatory CD8(+) T cells are involved in development and control of human autoimmune type 1 diabetes. J Clin Invest 2010;120:3641–50. This paper provides proof that a human HLA-E-restricted CD8+ T-cell subset displays a regulatory role in the periphery and proposes an avidity mechanism of peripheral tolerance that is altered in T1D.PubMedCrossRefGoogle Scholar
  25. 25.
    • Diana J, Brezar V, Beaudoin L, et al. Viral infection prevents diabetes by inducing regulatory T cells through NKT cell-plasmacytoid dendritic cell interplay. J Exp Med 2011 208:729–45. The interaction between innate and adaptive immune cells is dissected to explain its opposing role in mounting viral-specific responses and in blunting autoimmunity in mouse models.PubMedCrossRefGoogle Scholar
  26. 26.
    Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100:8372–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004;199:1455–65.PubMedCrossRefGoogle Scholar
  28. 28.
    Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol. 2006;24:209–26.PubMedCrossRefGoogle Scholar
  29. 29.
    Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3:253–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001;167:1245–53.PubMedGoogle Scholar
  31. 31.
    Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–61.PubMedCrossRefGoogle Scholar
  32. 32.
    Gavin MA, Rasmussen JP, Fontenot JD, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature. 2007;445:771–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Yang XO, Nurieva R, Martinez GJ, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity. 2008;29:44–56.PubMedCrossRefGoogle Scholar
  34. 34.
    Tang Q, Adams JY, Penaranda C, et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity. 2008;28:687–97.PubMedCrossRefGoogle Scholar
  35. 35.
    Komatsu N, Mariotti-Ferrandiz ME, Wang Y, et al. Heterogeneity of natural Foxp3+ T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA. 2009;106:1903–8.PubMedCrossRefGoogle Scholar
  36. 36.
    • Zhou X, Bailey-Bucktrout SL, Jeker LT, et al. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 2009;10:1000–7. This paper supports the notion of plasticity of murine Tregs, which can convert into pathogenic Teffs in vivo.PubMedCrossRefGoogle Scholar
  37. 37.
    • Rubtsov YP, Niec RE, Josefowicz S, et al. Stability of the regulatory T cell lineage in vivo. Science 2010;329:1667–71. At variance with the previous paper, this report contends that murine Tregs display a stable phenotype in vivo.PubMedCrossRefGoogle Scholar
  38. 38.
    McClymont SA, Putnam AL, Lee MR, et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol. 2011;186:3918–26.PubMedCrossRefGoogle Scholar
  39. 39.
    Putnam AL, Brusko TM, Lee MR, et al. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 2009;58:652–62.PubMedCrossRefGoogle Scholar
  40. 40.
    Floess S, Freyer J, Siewert C, et al. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 2007;5:e38.PubMedCrossRefGoogle Scholar
  41. 41.
    Thornton AM, Korty PE, Tran DQ, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol. 2010;184:3433–41.PubMedCrossRefGoogle Scholar
  42. 42.
    Yang XO, Pappu BP, Nurieva R, et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity. 2008;28:29–39.PubMedCrossRefGoogle Scholar
  43. 43.
    Qin H, Wang Z, Du W, et al. Killer cell Ig-like receptor (KIR) 3DL1 down-regulation enhances inhibition of type 1 diabetes by autoantigen-specific regulatory T cells. Proc Natl Acad Sci USA. 2011;108:2016–21.PubMedCrossRefGoogle Scholar
  44. 44.
    Verge CF, Stenger D, Bonifacio E, et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop. Diabetes. 1998;47:1857–66.PubMedCrossRefGoogle Scholar
  45. 45.
    Enee E, Martinuzzi E, Blancou P, et al. Equivalent specificity of peripheral blood and islet-infiltrating CD8+ T lymphocytes in spontaneously diabetic HLA-A2 transgenic NOD mice. J Immunol. 2008;180:5430–8.PubMedGoogle Scholar
  46. 46.
    Willcox A, Richardson SJ, Bone AJ, et al. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol. 2009;155:173–81.PubMedCrossRefGoogle Scholar
  47. 47.
    Mannering SI, Wong FS, Durinovic-Bello I, et al. Current approaches to measuring human islet-antigen specific T cell function in type 1 diabetes. Clin Exp Immunol. 2010;162:197–209.PubMedCrossRefGoogle Scholar
  48. 48.
    Mallone R, Mannering SI, Brooks-Worrell BM, et al. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin Exp Immunol. 2011;163:33–49.PubMedCrossRefGoogle Scholar
  49. 49.
    Brooks-Worrell B, Tree T, Mannering SI, et al. Comparison of cryopreservation methods on T cell responses to islet and control antigens from type 1 diabetes patients and controls. Diabetes Metab Res Rev 2011, in press.Google Scholar
  50. 50.
    Seyfert-Margolis V, Gisler TD, Asare AL, et al. Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study. Diabetes. 2006;55:2588–94.PubMedCrossRefGoogle Scholar
  51. 51.
    Herold KC, Brooks-Worrell B, Palmer J, et al. Validity and reproducibility of measurement of islet autoreactivity by T-cell assays in subjects with early type 1 diabetes. Diabetes. 2009;58:2588–95.PubMedCrossRefGoogle Scholar
  52. 52.
    Mallone R, Scotto M, Janicki CN, et al. Immunology of Diabetes Society T-cell workshop: HLA class I tetramer-directed epitope validation initiative. Diabetes Metab Res Rev 2011; In press.Google Scholar
  53. 53.
    James EA, Mallone R, Schloot NC, et al. Immunology of Diabetes Society T-cell workshop: HLA class II tetramer-directed epitope validation initiative. Diabetes Metab Res Rev 2011; In press.Google Scholar
  54. 54.
    • Fourlanos S, Perry C, Gellert SA, et al. Evidence that nasal insulin induces immune tolerance to insulin in adults with autoimmune diabetes. Diabetes 2011;60:1237–45. This paper is the first to document Ag-specific tolerance restoration both at the T-cell and antibody level following intranasal insulin administration in T1D patients.PubMedCrossRefGoogle Scholar
  55. 55.
    Martinuzzi E, Afonso G, Gagnerault MC, et al. Accelerated co-cultured dendritic cells (acDCs) enhance human antigen-specific T-cell responses. Blood 2011; doi: 10.1182/blood-2010-12-326231

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.INSERM U986, DeAR Lab AvenirParis, Cedex 14France
  2. 2.Université Paris-DescartesParisFrance
  3. 3.Assistance Publique Hôpitaux de ParisParisFrance

Personalised recommendations